Immunovant (NASDAQ:IMVT) advances autoimmune research as nasdaq today reflects activity across clinical-stage biotech ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...

At this year's American College of Rheumatology (ACR) annual meeting, researchers highlighted emerging approaches aimed at defining precision medicine in Sjögren's disease, including advances in ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Learn more about whether Viridian Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Trey Kukuk completó un pase de touchdown antes de realizar un gran acarreo que dejó lista la escena para que Andrew Burnette ...

Multiple myeloma (MM) is the second most common hematologic malignancy, characterized by the uncontrolled growth of plasma cells and progressive ...

Curious about the animals most often used in research? Get to know the top five—like mice, rabbits, and goats—and the roles they play in scientific studies.